EuniceWangMD

Hematologic Oncology

Chief, Clinical Leukemia Service and Professor of Oncology, Dept Medicine, Roswell Park Cancer Institute; Associate Professor, Dept Medicine, University of Buffalo (UB) SUNY School of Medicine; and Associate Director, UB/RPCI Hematology-Oncology Fellowship

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wang's full profile

Already have an account?

Office
Elm And Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-8741
Is this information wrong?

Summary

I am a hematologist-oncologist and physician scientist whose clinical practice focuses on the treatment of patients with acute and chronic leukemia, myeloid disorders, and benign hematological conditions.

Education & Training

Memorial Sloan Kettering Cancer Center1999 - 2003
Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 1999
Keck School of Medicine of the University of Southern CaliforniaClass of 1996
Harvard UniversityBA, Biology, Cum Laude, 1987 - 1991

Certifications & Licensure

NY State Medical License 1999 - 2025

Clinical Trials

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2015 Jun 30
Active, not recruiting
Phase 2
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Start of enrollment: 2015 Feb 01
Terminated
Phase 1, Phase 2
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations Start of enrollment: 2015 Jan 01
Completed
Phase 2
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Start of enrollment: 2014 Nov 01
Completed
Phase 1, Phase 2
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2016 Jul 11
Terminated
Phase 1
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 May 01
Terminated
Phase 3
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2021 Jan 21
Withdrawn
Phase 1, Phase 2
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome Start of enrollment: 2021 May 01
Withdrawn
Phase 1, Phase 2
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Start of enrollment: 2020 Jan 15
Terminated
Phase 2
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Oct 23
Recruiting
Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Start of enrollment: 2018 Mar 19
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Tagraxofusp (SL-401) in Patients With CMML or MF Start of enrollment: 2014 Dec 01
Completed
Phase 2
Roles: Principal Investigator, Contact
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Start of enrollment: 2018 Jan 02
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Start of enrollment: 2018 Oct 04
Active, not recruiting
Phase 3
Roles: Principal Investigator
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes Start of enrollment: 2024 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Mark J Levis, Alexander E Perl, Gary J Schiller, Amir T Fathi, Gail J Roboz, Eunice S Wang, Jessica K Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann...> ;Blood Advances. 2024 Mar 19
1 citations
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Rizzieri, D., Pemmaraju, N., Madanat, Y., Fazal, S., Rampal, R., Mannis, G., Wang, E., Foran, J., Lane, A., Fazal, S.> ;Leukemia & Lymphoma. 2024 Feb 23
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
Vigil, C., Collins, R., Jain, V., Wang, E., Goldberg, A., Tallman, M., Walter, R., Karanes, C., Sandhu, K., Stone, R.> ;Journal of Clinical Oncology. 2024 Feb 7
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppu...> ;Blood. 2023 Dec 21
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refra...
Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman, Eunice S Wang, Amer M Zeidan> ;Annals of Hematology. 2023 Nov 1
2 citations
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...
Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, ...> ;Journal of Clinical Oncology. 2023 Nov 1
1 citations
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
Hassan Awada, Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark Faber, Matthew Gravina, Pamela J Sung, Steven D ...> ;Blood Cancer Journal. 2023 Sep 4
3 citations
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype.
You-Wen Qian, Eunice S Wang, Sheila Jani Sait, Sean T Glenn> ;Cancer Genetics. 2023 Nov 1
MDM2 and BCL-2: to p53 or not to p53?
Eunice S Wang> ;Blood. 2023 Mar 16
4 citations
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress.
Nancy Issa, Hassan Bjeije, Elisabeth R Wilson, Aishwarya Krishnan, Wangisa M B Dunuwille, Tyler M Parsons, Christine R Zhang, Wentao Han, Andrew L Young, Zhizhong Ren,...> ;Leukemia. 2023 Apr 1
15 citations
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): hae...
David A Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Eunice S Wang, Jason B Brayer, Marco L Davila, Ine Moors, Jean-Pascal Machiels, Ahmad...> ;The Lancet. Haematology. 2023 Mar 1
1 citations
Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis.
Farhan Azad, Jiahua Zhang, Eunice Wang> ;Proceedings. 2023 Jan 1
9 citations
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versu...
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ehab Atallah, Gary J Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge...> ;Transplantation and Cellular Therapy. 2023 Apr 1
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famu...> ;Blood. 2023 Mar 23
12 citations
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
36 citations
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J Schiller, Shira N Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S Wang, Karen P Seiter, And...> ;The Lancet. Haematology. 2023 Jan 1
5 citations
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis...
Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice Wang, Aaron Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, S...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
2 citations
A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges.
Hassan Awada, Moaath K Mustafa Ali, Bicky Thapa, Hussein Awada, Leroy Seymour, Louisa Liu, Carmelo Gurnari, Ashwin Kishtagari, Eunice Wang, Maria R Baer> ;Cancers. 2022 Aug 28
45 citations
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Eunice S Wang, Pau Montesinos, Mark D Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K Altman, Violaine Havelang...> ;Blood. 2022 Oct 27
8 citations
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres, M., Schuster, M., Joris, M., Krauter, J., Maertens, J., Breems, D., Gyan, E., Kovacsovics, T., Verma, A., Vyas, P., Wang, E., Ching, K., O'Brien, T., Gallo St...> ;Annals of Hematology. 2022 Aug 1
14 citations
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, Eunice S Wang, David A Rizzieri, Sumithira Vasu, Todd L Rosenblat, Christopher L Brooks, Nassir Habboubi, Tariq I Mu...> ;Journal of Clinical Oncology. 2022 Sep 10
Join now to see all

Journal Articles

NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome
Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Feasibility of Flow Cytometric Identification and Isolation of Pre-Platelets to Understand Its Function and Role in Cancer Metastasis
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A ...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Quantification of Humoral Immune Response to Influenza Vaccination in MDS
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant Abstract
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

AML: Expert Guidance on Current Standards and New Directions in Patient Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Moving Toward Precision Therapy for Patients with AML: Clinical Challenges and Future Directions
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRTJune 9th, 2021
Roswell Park Researchers Gear up for ASCO 2021 Annual MeetingJune 3rd, 2021
Argenx’s Cusatuzumab in Previously Untreated AML Draws Varied Expert Forecasts for Safety Potential in Phase IbFebruary 24th, 2021
Join now to see all

Committees

Member, Scientific Review Committee 2009 - Present
Member, Fellowship Program Committee 2007 - Present

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member

Hospital Affiliations

KALEIDA HealthBuffalo, New York
Sisters of Charity Hospital of BuffaloBuffalo, New York
Roswell Park Comprehensive Cancer CenterBuffalo, New York

External Links

roswellpark.orghttps://www.roswellpark.org/eunice-wang
roswellpark.eduhttps://www.roswellpark.edu/eunice-wang
buffalo.eduhttps://medicine.buffalo.edu/content/medicine/faculty/profile.html?ubit=ewang3